344079-M

Flurbiprofen

A mixture of S(+) and R(-) enantiomers.

• Synonyme(s) : Flurbiprofen, (±)-2-Fluoro-α-methyl[1,1ʹ-biphenyl]-4-acetic Acid, U-27182
• Formule empirique (notation de Hill): C₁₅H₁₃FO₂
• Numéro CAS: 5104-49-4
• Poids moléculaire : 244.26
• Numéro MDL: MFCD00079303
• Code UNSPSC : 12352200

Propriétés

• Niveau de qualité: 100
• Pureté: ≥98% (HPLC)
• Forme: solid
• Fabricant/nom de marque: Calbiochem^®
• Conditions de stockage: OK to freeze
• Couleur: white
• Solubilité: DMSO: 50 mg/mL
• Température de stockage: 10-30°C
• InChI: 1S/C15H13FO2/c1-10(15(17)18)12-7-8-13(14(16)9-12)11-5-3-2-4-6-11/h2-10H,1H3,(H,17,18)
• Clé InChI: SYTBZMRGLBWNTM-UHFFFAOYSA-N

Description

Description générale

A mixture of S(+) and R(–) enantiomers. A cell-permeable, non-steroidal anti-inflammatory agent that acts as a potent inhibitor of cyclooxygenase (IC₅₀ = 5 nM for LPS-induced COX in human peripheral blood cells). Strongly inhibits insoluble transthyretin (TTR) amyloid fibril formation. Suppresses iNOS expression in RAW 264.7 macrophages. Reduces microglial activation and β-amyloid deposit in APP+PS1 transgenic mice.

A mixture of S(+) and R(-) enantiomers. A cell-permeable, non-steroidal anti-inflammatory (NSAID) agent that acts as a potent inhibitor of cyclooxygenase (IC₅₀ = 5 nM for LPS-induced COX in human peripheral blood cells). The S(+) enantiomer is reported to be more potent as a COX-2 inhibitor than the R(-) enantiomer. Suppresses iNOS expression in RAW 264.7 macrophages. Reduces Aβ loads and Congo Red staining in APP+PS1 transgenic mice

Actions biochimiques/physiologiques

Primary Target
Cyclooxygenase

Target IC₅₀: 5 nM for LPS-induced COX

Avertissement

Toxicity: Toxic & Carcinogenic / Teratogenic (G)

Reconstitution

Following reconstitution, aliquot and freeze at -20°C. Stock solutions are stable for up to 6 months at 4°C. Further dilution of stock solution in aqueous medium should be made just prior to use.

Autres remarques

Jantzen, P.T., et al. 2002. J. Neurosci.22, 2246.
Hinz, R., et al. 2001. Pharmacol. Res.18, 151.
Klabunde, T., et al. 2000. Nat. Struct. Biol.7, 312.
Range, S.P., et al. 2000. Eur. Respir. J.15, 751.
van Haeringen, N.J., et al. 2000. J. Ocul. Pharmacol. Ther.16, 353.
Curnock, A.P., et al. 1997. J. Pharmacol. Exp. Ther.282, 339.
Reindeau, D., et al. 1997. Can. J. Physiol. Pharmacol.75, 1088.
Wechter, W.J., et al. 1997. Cancer Res. 57, 4316.
Karmali, R.A., and Marsh, J. 1986. Prostaglandins Leukot. Med. 23, 11.
Karmali, R.A., and Marsh, J. 1985. Prostaglandins Leukot. Med. 20, 283.

Informations légales

CALBIOCHEM is a registered trademark of Merck KGaA, Darmstadt, Germany

Informations sur la sécurité

• Pictogrammes: GHS06
• Mention d'avertissement: Danger
• Mentions de danger: H301
• Conseils de prudence: P264 - P270 - P301 + P310 - P405 - P501
• Classification des risques: Acute Tox. 3 Oral
• Code de la classe de stockage: 6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects
• Classe de danger pour l'eau (WGK): WGK 3
• Point d'éclair (°F): Not applicable
• Point d'éclair (°C): Not applicable